3.8 Article

Hormonal fertility treatment and the Prohibited List of the World Anti-Doping Agency (WADA)

Journal

GYNAKOLOGISCHE ENDOKRINOLOGIE
Volume 19, Issue 3, Pages 190-195

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s10304-021-00402-w

Keywords

National Anti-Doping Agency; Therapeutic Use Exemption; Sports; Assisted reproductive treatment; Infertility

Ask authors/readers for more resources

This article discusses the use of prohibited hormonal fertility treatment ingredients in sports, including treatments for female ovulation stimulation and male infertility. It also emphasizes the importance of athletes undergoing fertility treatment in compliance with anti-doping regulations.
Many active ingredients used for hormonal fertility treatment are part of the so-called Prohibited List that applies in sports. In women, gonadotropin-releasing hormone (GnRH) receptor agonists or antagonists, gonadotropins, antiestrogens and/or aromatase inhibitors are used to stimulate ovulation. After the follicle puncture and into pregnancy, gestagens and human chorionic gonadotropin support the maintenance of the pregnancy. In cases of male infertility, aromatase inhibitors and antiestrogens used off-label can improve sperm production and mobility. Of course, competitive athletes should not be denied the possibility of assisted reproductive treatment per se. This article explains the current anti-doping regulations, the process for approval of the use of prohibited substances by athletes and contains tips on how treating physicians can provide support, so that hormonal fertility treatment can be carried out in accordance with the anti-doping rules.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available